Testing a new drug for mild to moderate Alzheimer's
Part of Brain & nervous system, Mental health clinical trials.
This trial tests an experimental drug called sodium pentaborate pentahydrate (a boron-based compound) in people with mild to moderate Alzheimer's. Researchers want to see if it's safe and if it can help slow memory and thinking problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 55 and 85 years old.
- A doctor must have diagnosed you with mild to moderate Alzheimer's disease.
- You need to have some memory trouble that is worse than expected for your age.
- You must be taking a steady dose of Alzheimer's medication (if you take any).
- You cannot have other major brain or mental health problems (like stroke, Parkinson's, or severe depression).
- You cannot have had certain findings (bleeding or swelling) on a previous brain MRI.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (BnH-015B) for people with moderate Alzheimer's disease. It also includes a small group of healthy young men for comparison. The goal is to see if the drug is safe and how it works in the body.
This study tests an investigational drug called BEY2153 for people with early Alzheimer's disease (mild cognitive impairment or mild dementia). The goal is to see if it is safe and slows down memory decline.
This study tests a new drug called NSC001 for people with mild to moderate Alzheimer's. It checks if the drug is safe and if it might help slow memory decline. You'll need a caregiver who can join you at visits and help track your progress.
This study tests an experimental drug for Alzheimer's called NTRX-07. It aims to see if it can slow memory decline for people with mild to moderate Alzheimer's.
This Phase 2 study tests whether sargramostim (a GM-CSF related medicine) is safe and can slow or improve Alzheimer’s symptoms. You might be a good fit if you have mild or moderate Alzheimer’s, positive amyloid testing, and can complete frequent visits with a close caregiver who knows you well.
This Phase 2 trial tests an oral medicine (EX039) to see if it can help people with mild Alzheimer’s disease. It focuses on slowing or improving thinking and memory problems over time.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.